SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
A. J. Njouendou, A. A. Z. Tiofack, R. N. Kenfack…·S. S. Lueong
The paper identifies SOX2 amplification as a driver of tumor aggressiveness by sustaining inflammation through the FOSL2/IL6 axis, leading to DNA damage and genome instability.